Actoxumab is a human

monoclonal Monoclonality refers to the state of a line of cells that have been derived from a single clonal origin. Thus "monoclonal cells" can be said to form a single clone. The term ''monoclonal'' comes from the Ancient Greek ''monos'', meaning "alone" o ...

antibody designed for the prevention of recurrence of '' Clostridium difficile'' infection. This drug, along with

bezlotoxumab Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of ''Clostridioides difficile'' infections. This drug, along with actoxumab, was developed through Phase II efficacy trials ...

, was developed through Phase II efficacy trials by a partnership between

Medarex Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. ...

Inc and MassBiologics of the

University of Massachusetts Medical School The University of Massachusetts Chan Medical School is a public medical school in Worcester, Massachusetts. It is part of the University of Massachusetts system. It is home to three schools: the T.H. Chan School of Medicine, the Morningside Grad ...

. The project was then licensed to Merck & Co., Inc. for further development and commercialization. A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.New treatment for C.diff infections reduces recurrences by 40%, study finds
/ref>

References

Monoclonal antibodies Experimental drugs {{monoclonal-antibody-stub